We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Yeast Protein Prevents Toxic Shock Syndrome

By Biotechdaily staff writers
Posted on 04 Jun 2007
Researchers working with advanced genetic engineering techniques used yeast to create a soluble protein that successfully protected rabbits against the toxic effects of Staphylococcus aureus enterotoxin B (SEB).

Exotoxins of S aureus belong to a family of bacterial proteins that act as superantigens by activating a large subset of the T-cell population, causing massive release of inflammatory cytokines. This cascade can ultimately result in toxic shock syndrome and death.

Investigators at the University of Illinois (Urbana-Champaign, USA) capitalized on a technique they had developed for expressing protein antigens on the surface of yeast cells. The expressed proteins can then be mutated and amplified. In this case, the expressed protein had the same structure as the binding site of the T-cell receptor targeted by SEB. The gene for the binding protein was inserted into Esherichia coli, which produced large quantities of the protein in a soluble form.

Results published in the May 21, 2007, online edition of the journal Nature Medicine revealed that these soluble proteins were effective inhibitors of SEB-mediated T-cell activation and completely neutralized the lethal activity of SEB in animal models.

"We were very pleasantly surprised that it showed effectiveness in every rabbit tested,” said senior author Dr. David M. Kranz, professor of biochemistry at the University of Illinois. "Our approach was to take these receptors that bind to the toxins and to try to make them higher affinity and therefore act as effective neutralizing agents when delivered in soluble form. It is the binding of the toxin to T-cells that is critical. If you can prevent the toxin from binding to the T-cell receptor, then you can prevent it from initiating that cascade.”


Related Links:
University of Illinois

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
Electrolyte Analyzer
BKE-B
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5

Latest BioResearch News

Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
04 Jun 2007  |   BioResearch

Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
04 Jun 2007  |   BioResearch

Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer
04 Jun 2007  |   BioResearch



ADLM